Safety and Immunogenicity of Nanocovax, a SARS-CoV-2 Recombinant Spike Protein Vaccine

2.1. Trial design and oversight

Phase 1 trial was conducted at the Military Medical University, Ha Noi, Vietnam. This was an open-labeled, dose-escalation study with the emphasis on the vaccine safety (figure S1). Eligible participants were healthy men and nonpregnant women, 18 to 50 years of age with body-mass index (BMI) of 18 to 27 kg/m² (table S2). In this phase, 60 participants were allocated into 2:2:2 ratio of 25 μg, 50 μg and 75 μg dose groups, respectively. For safety measure, the first 3 participant of 25 μg dose group were vaccinated and monitored for 72 hours. After no SAE were observed, all remaining participants in this group plus 3 participants in 50 μg dose group would be vaccinated and monitored for 72 hours. If no SAE were observed among 3 participants of 50 dose group, the remaining participant in this group plus 3 participants in 75 μg dose group would be vaccinated. If no SAE were observed among 3 participants in 75 μg dose group, the remaining participants in this group will be vaccinated. All participants received 2 intramuscular injections of the vaccine into the deltoid on day 0 and day 28. Sample size of phase 1 was not based on formal statistical power calculation but on the range of 30 – 150 recommended in Article 10 of Appendix 10/2020/TT-BYT by Vietnam Ministry of Health.

Phase 2 trial was conducted at two sites: Military Medical Academy, Ha Noi and the Pasteur Institute at Ho Chi Minh city, Vietnam. This was a randomized, double-blind, placebo-controlled study (figure 1). Eligible participants were healthy men and nonpregnant women, at least 18 years of age with BMI of 17 to 35. They were stratified into 3 age groups: from full 18 to full 45 years old, from 46 to 60 years old, and over 60 years old (table S2). The sample size of phase 2 was calculated based on the estimated probability of observing an adverse event. Accordingly, a total of 560 participants will be randomly assigned to 4 groups, into 2:2:2:1 ratio for 25 μg, 50 μg, 75 μg, and placebo, respectively. In details, 480 volunteers would receive the vaccine (160 volunteers receiving 25 µg dose; 160 volunteers receiving 50 µg dose and 160 volunteers receiving dose of 75 µg dose) and 80 volunteers would receive the placebo (aluminum adjuvant only). All participants received 2 intramuscular injections of the vaccine or the placebo into the deltoid on day 0 and day 28. Trial staffs responsible for the vaccine preparation and administration, and participants were unaware of vaccine assignment. Randomization lists, using block randomization stratified by study group and study site, were generated by the study statistician. Computer randomization was done with full allocation concealment within the secure web platform used for the study electronic case report form (service provided by Medprove company).

• Download figure
• Open in new tab

Figure 1.

Screening and randomization of participants in phase 2.

All participants were screened by their medical history, clinical and biological examinations, sampling and laboratory tests (complete blood count, biochemistry, urine analysis, testing pregnancy and diagnostic imaging). Participants with a history of Covid-19 or positive results for SARS-CoV-2 at screening period confirmed by real-time reverse transcriptase polymerase-chain-reaction (RT-PCR) were excluded from the trials. All participants provided written consent before being enrolled into the trial.

The trials were designed and funded by Nanogen Pharmaceutical Biotechnology JSC and the Ministry of Science and Technology (MOST) of Vietnam. The trial protocol was approved by the Ethics Committee/Protocol Review Board of the Ministry of Health (Vietnam) and was performed in accordance with the ICH-GCP good clinical practice guidelines, with an ethical policy consistent with the “Declaration of Helsinki” and applicable Vietnamese laws and regulations. The authors take responsibility for the integrity of the data and the fidelity of the trial to the protocol.

2.2. Trial vaccine, adjuvant, and placebo

The recombinant SARS-CoV-2 spike (S) glycoprotein in Nanocovax were constructed with 682-QQAQ-685 mutations for protease resistance, and two proline substitutions (K986P and V987P) for stabilized prefusion conformation. The production of the full-length (including the transmembrane domain) recombinant S protein was optimized in the established Chinese Hamster Ovary (CHO) cell-expression system. Clinical grade aluminum hydroxide was manufactured by Croda (Denmark). Recombinant SARS-CoV-2 S protein were absorbed to aluminum adjuvant in mild shaking condition for 18 hours at 2°C to 8°C. Placebo was sterile 0.05% aluminum.

2.3. Safety assessments

In phase 1, the onsite safety follow-up time after was 72 hours after 1^st injection and 24 hours after the 2^nd injection. Participants would return to the study site for follow-up visits at scheduled timepoints (table S1). In phase 2, the onsite safety follow-up time was 60 minutes after each vaccination. Follow-up visits to evaluate safety were scheduled on days 28, 35, 42, 90, 180 after vaccination (table 1). Participants were observed for 60 minutes after each vaccination for assessment of reactogenicity. In both phases, participants received instruction for self-monitoring and reporting adverse events during 7 days after each vaccination, as facilitated by the use of a diary with predefined reactogenicity. Predefined local (injection site) reactogenicity included pain, tenderness, erythema, and swelling. Predefined systemic reactogenicity included fever, nausea or vomiting, headache, fatigue, malaise, myalgia, and arthralgia. Vaccination pause rules were in place to monitor participants’ safety (Supplementary appendix).

The primary safety outcomes were the number and percentage of participants with solicited local and systemic adverse events occurred within 7 days after vaccination and laboratory results (serum chemistry and hematology) at days 0, 7, 28, 35 according to FDA toxicity scoring⁷. Secondary safety outcomes were occurrence rate and severity rating of unsolicited AE/SAE through day 56 and laboratory results at days 42 and 56 (phase 2 and 1, respectively).

AEs/SAEs were recorded and evaluated basing on the Common Terminology Criteria for Adverse Events 5.0 (CTCAE v5.0) and Guidelines for assessing toxicity in healthy volunteers in FDA’s Preventive Vaccine Clinical Trial Study^7,8. The procedures for recording and evaluating take place continuously from the time of using the first dose to the end of the last visit in each research volunteer. Adverse events were assessed in terms of severity score (mild, moderate, severe, life-threatening, or fatal), and relatedness to the vaccine. Vital sign measurements were assessed according to FDA toxicity scoring after vaccination. In addition, participants underwent nasopharyngeal swab testing for SARS-CoV-2 on screening day (before 1^st vaccination), day 28 (before 2^nd vaccination) and any time that they developed symptoms of possible SARS-CoV-2 infection.

2.4. Immunogenicity assessments

The primary outcome was anti-S IgG responses to Nanocovax evaluated by chemiluminescence immunoassay (CLIA). Secondary outcomes were neutralizing antibody titer evaluated by 50 percent plaque reduction neutralization test (PRNT₅₀) on Wuhan strain and UK variant (B.1.1.7), neutralizing activity evaluated by competitive enzyme-linked immunosorbent assay (ELISA) based surrogate virus neutralization test (sVNT), and T cell response by intracellular cytokine-staining (ICS). Details of these assays are provided in the supplementary appendix.

2.5. Statistical analysis

3.1. Trial population

The phase 1 trial was started on December 17, 2020. 60 participants underwent randomization into 3 groups of doses: 20 received 25 mcg (group 1.1), 20 received 50 mcg (group 1.2), and 20 received 75 mcg (group 1.3). There was no placebo group for this stage of study, and the primary assessment was the vaccine safety.

For phase 2, the study was started on February 26, 2021. 560 participants were recruited and randomly assigned into groups of different doses: 161 received 25 mcg doses of Nanocovax (group 2.1), 160 received 50 mcg doses of Nanocovax (group 2.2), 159 received 75 mcg doses of Nanocovax (group 2.3), and 80 received placebo (group 2.4). Participants were stratified into 2 age groups: from over 18 to below 60 years old and over 60 years old. Demographic characteristics of participants in phase 1 and 2 are shown in table 1 and table S1.

3.2. Safety outcomes

In phase 1, no serious adverse events were observed, and vaccination pause rules were not implemented. Overall reactogenicity was largely absent or mild, and second vaccinations were neither withheld nor delayed due to reactogenicity. The percentage of participants in each vaccine group (groups 1.1, 1.2, and 1.3) with solicited adverse events according to the maximum FDA toxicity grade (grade 1: mild, grade 2: moderate, grade 3: severe, grade 4: life-threatening) during the period of this study was presented in figure S2. These preliminary results showed that Nanocovax were safe at all dose strength: 25 mcg, 50 mcg, and 75 mcg.

In phase 2, among 560 participants, there were 554 participants receiving full 2 dose of vaccine or placebo (figure 1). 6 withdrew from the study after the 2^nd visit, before getting the boosting dose. Local AE were 37.7% after 1st vaccination and 35.6% after 2nd vaccination. Local pain were 32.6% (181/556) after 1st injection and 32.1% (178/554) after 2nd injection. Systemic AEs were 27.4% after 1^st injection and 21.8% after 2^nd injection. Most common systemic AEs were fatigue (16.9%/13%), headache (13.3%/8.3%) and fever (3.8%/2.4%) after 1^st/2^nd injections. After 1^st injection, local and systemic AE of grade 3 or 4 were not observed in group 2.1, 1 case in group 2.2 (0.6%), 1 case in group 2.3 (0.6%) and 1 case in group 2.4 (1.3%). After 2^nd injection, local and systemic AE of grades 3 or 4 were 1 in each vaccine group (0.6%) and placebo (1.3%) (figure 2).

• Download figure
• Open in new tab

• Download figure
• Open in new tab

Figure 2.

Solicited local adverse event (A) and systemic adverse events (B) within 7 days after vaccination in phase 2.

The incidence of unsolicited AEs in were similar in vaccine groups and the placebo (appendix 7). In details, unsolicited AE incidence of groups 2.1 to 2.4 were 30.4%, 27.5%, 23.3% and 33.8%, respectively. Two cases of grade 4 AE were back pain and dizziness. There were five AE of grade 3: 1 case of sepsis, 1 case of back pain, 1 case of spondylolisthesis, 1 case of sore throat, 1 case of high blood pressure. The most frequently reported adverse events were sore throat 27 (4.8%) and coughing 11 (2%). The most laboratory-related AEs were hyperglycemia 13 cases (2.3%), leukocytosis: 8 cases (1.4%), the most vital events related to hypothermia with 12 cases (2.1%). In similar to phase 1, vaccination pause rules were not implemented in phase 2. Four SAE were determined unrelated to Nanocovax, including 1 case of angina (history of stent graft), 1 case of fever (determined to be sepsis), 1 case of abscess at axillary lymph nodes occurred on the unvaccinated arm and 1 case of personal injury. One case SAE grade 1 of anaphylaxis was undetermined to be related to vaccine or not because the symptoms were not clear (table S3).

The percentage of participants in each vaccine group (groups 2.1, 2.2, 2.3, and 2.4) with adverse events according to the maximum FDA toxicity grade during the 7 days after each vaccination were plotted for solicited local and systemic adverse events (figure 2). There were no grade 4 events. The most adverse event was pain at the injection site, mild pain (grade 1) accounted for 23.4% (130/556) after 1st injection and accounted for 26.9% (149/554) after 2nd injection. Moderate pain (grade 2), was uncommon, accounted for 0.4% (2/556) after the 1st injection and 1.1% (6/554) after the 2nd injection. Mild sensitivity at the injection site accounted for 14.7 % (82/556) after 1st injection and 14.3% (79/554) after 2nd injection. Moderate sensitivity accounted for 4% (22/556) after injection 1 and 3.8% (21/554) after injection 2. The severe event (grade 3) was “pain at injection site” appearing in 1 subject after 2nd injection, accounting for 0.2% (1/554) and “redness at injection site” occurring in 2 subjects (2/554) after 2nd injection. The events mostly occurred within 2 days after vaccination, gradually decreased and disappeared within 7 days after vaccination. Some subjects felt fatigue after injection, accounting for 9.4% (52/556) after 1st injection and 8.3% (46/554) after 2nd injection. Fatigue decreased gradually day by day, disappeared at about 7 days after injection. The event “fever” occurred in relatively few subjects, mild fever accounted for 0.2% (1/556) after 1st injection and 1.1% (6/554) after 2nd injection. There was 1 subject with high fever (grade 3) accounted for 0.2% (1/556), occurred from day 1 to day 5 after 2nd injection. In the phase 2 study, the proportion of subjects with any “unsolicited” AE after injection with vaccine and placebo was 157/560 (28%). The rates of any AE in the study groups were similar between the 25 mcg (30.4%), 50 mcg (27.5%), 75 mcg (23.3%) and placebo (33.8%) groups. Most of “unsolicited” AEs were mild to moderate. When comparing the overall incidence of unsolicited AEs between the vaccine and placebo groups, the rates were similar in the two groups, with a ratio of 130/480 (27.1%) in the vaccinated group compared to the ratio of 27/80 (33.8%) in the placebo group.

Laboratory abnormalities in phase 2 included increased white blood cell in 3 participants, (0.6%), increased neutrophil in 2 participants (0.4%), elevated ALT (grade 2) in 3 participants (0.6%), and elevated AST (grade 2) in 2 participants (0.4%). The other biochemistry and hematology parameters such as red blood cell (RBC), hemoglobin (HGB), creatinine, bilirubin, prothrombin time (PT) fluctuated within normal limits (appendix 7).

3.3. Immunogenicity outcomes

Anti-S IgG antibody in the serum was quantified by CLIA. Geometric mean concentration (GMC) of anti-S IgG (U/ml) was reported. Before the first injection, the GMC values of the 4 groups were all below the lower limit of detection. Anti-S IgG GMC of 3 vaccine groups increased sharply after 2nd injection, on day 35 and day 42 (figure 3). On day 35, GMC of group 2.1, 2.2 and 2.3 were 6.78 U/ml (95% CI: [5.09-9.03]), 9.38 U/ml [6.99 – 12.58], and 13.04 U/ml [9.46 – 17.98] respectively. GMC of group 2.3 was statistically higher than that of group 2.1 but not group 2.2. GMC of the pairs (2.1 vs 2.2) and (2.2 vs. 2.3) were not statistically different. On day 42, GMC of group 2.1, 2.2 and 2.3 increased sharply: 60.48 U/ml [51.12 - 71.55]; 49.11 U/ml [41.26 - 58.46] and 57.18 U/ml [48.4-67.5], respectively. Meanwhile, the GMC of the placebo group at days 35, and 42 were 0.29 U/ml [0.25 – 0.33], and 0.29 U/ml [0.25 – 0.32], respectively.

• Download figure
• Open in new tab

Figure 3.

Anti-S IgG antibody responses of vaccine and placebo groups, expressed in geometric mean concentration. Arrows indicate days of vaccination. I bar represents 95% confident intervals (95% CI).

Geometric mean fold rise (GMFR) of anti-S IgG was defined as the fold increase in GMC of a given timepoint compared to baseline GMC value of the same group on day 0. GMFR of 2.1, 2.2 and 2.3 groups on day 35 were 25.7 [19.3 – 34.1], 34.7 [25.7 – 46.9], and 49.8 [36.0 – 68.9], respectively. At day 42, the GMFR of 2.1, 2.2 and 2.3 groups were 229.0 [193.2-271.4], 181.8 [152.0 – 217.4] and 218.3 [185.0 – 257.7]. Meanwhile, the GMFR of the placebo group (2.4) on days 35 and 42 were 1.05 and 1.04 respectively (figure S4).

The seroconversion rate was defined as GMFR > 4. Based on the GMFR of anti-S IgG, the seroconversion rates of 2.1, 2.2 and 2.3 group on day 35 were 84%, 84% and 85%, respectively. On day 42, the seroconversion rate of 2.1, 2.2 and 2.3 groups were 100%, 99% and 100%, respectively (Figure S5).

Surrogate virus neutralization test (sVNT) results, expressed as inhibition percentage (%), were considered positive if they were higher than cut-off value of 30%⁹. On day 35, the mean sVNT of groups 2.1 to 2.4 were 58.5% [54.1 – 63.0], 63.8% [59.1 – 68.5], 70.2% [65.8 – 74.5], 11.1% [9.3 – 12.7), respectively. Accordingly, the proportions of participants positive for sVNT in groups 2.1 to 2.4 were 80.4%, 82.4%, 86.7% and 1.3%, respectively. On day 42, the mean sVNT of group 2.1 to 2.4 were 87.5% [85.5 – 89.5], 86.4% [84.08 – 88.65], 87.1% [85.06 – 89.16], and 10.8% [8.9 – 12.67], respectively. Accordingly, the proportions of participants positive for SVN in groups 2.1 to 2.4 were 100%, 100%, 99.4% and 1.3%, respectively (figure 4A).

• Download figure
• Open in new tab

Figure 4.

Neutralizing antibody responses. A) Surrogate virus neutralization was performed on all serum samples. Sera of day 0 were collected before 1^st injection. B) PRNT₅₀ on the original Wuhan strain was performed on 112 randomly selected serum samples including vaccine groups (n=32 each) and placebo (n=16). Results expressed as geometric mean with 95% confidence interval. Dashed line indicates lower limit of detection. Each data point represents a sample. I bar represents 95% CI.

Neutralizing antibody titers were evaluated by plaque reduction neutralization test with inhibitory dilution greater than 50% (PRNT₅₀). 112 serum samples of groups 2.1 to 2.4 were randomly selected for PRNT₅₀ on Wuhan strain and UK variant. The results were expressed as geometric mean titer (GMT). On day 35, GMT of groups 2.1 to 2.3 were 20.9 [12.8 - 34.1], 22.5 [14.5 – 34.7] and 33.6 [20.9 – 54.1]. GMT of group 2.3 was statistically higher than that of group 2.1. However, no statistical difference was found between the pairs (2.1 vs. 2.2) and (2.2 vs. 2.3). On day 42, GMT of vaccine groups were 89.2 [52.2 – 152.3], 80 [50.8 – 125.9] and 95.1 [63.1 – 143.6], almost 3-time increase, compared to day 35. Meanwhile, serum samples of the placebo group at days 35 and 42 did not show neutralizing activity (figure 4B). As a matter of interest, a small subset of 112 serum samples were randomly selected to test neutralizing activity against UK variant (B.1.1.7, also known as the alpha variant). As expected, neutralizing titer found on UK variant was similar to that of Wuhan strain (figure S7).

T cell responses of 84 randomly selected participants (28 for each vaccine group and 14 for placebo group) were undetectable (data not shown). This was likely due to the nature of aluminum adjuvant which has been well established for Th2 response induction.